Outcome by IKZF1 status in EsPhALL good-risk patients. DFS, CIR, and OS by IKZF1 status of all EsPhALL good-risk patients (A, B, and C, respectively) and DFS, CIR, and OS of EsPhALL good-risk patients treated with imatinib (D, E, and F, respectively), with 4-year estimates (SE). CR1, first complete remission.